Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

33.58
-1.7000-4.82%
Post-market: 33.600.0200+0.06%16:44 EDT
Volume:795.94K
Turnover:26.90M
Market Cap:2.18B
PE:-11.26
High:35.32
Open:34.48
Low:33.47
Close:35.28
Loading ...

Why Kymera Therapeutics Stock Crushed it This Week

Motley Fool
·
26 Apr

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

GlobeNewswire
·
24 Apr

Kymera Therapeutics Inc - KT-621 Phase 1 Healthy Volunteer Trial Data Expected in June 2025

THOMSON REUTERS
·
22 Apr

Kymera Therapeutics Announces First Patient Dosed in Broaden Phase 1B Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral Stat6 Degrader

THOMSON REUTERS
·
22 Apr

Kymera Therapeutics Inc - Phase 2B Trials in Ad and Asthma to Start in 4Q25 and 1Q26

THOMSON REUTERS
·
22 Apr

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

GlobeNewswire
·
22 Apr

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

Zacks
·
10 Apr

Kymera Therapeutics appoints Goodman as Chief Business Officer

TIPRANKS
·
09 Apr

Press Release: Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Dow Jones
·
09 Apr

Top Analyst Reports for Shell, Uber & TotalEnergies

Zacks
·
20 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar

BUZZ-Citigroup starts coverage of Kymera with $52 PT

Reuters
·
13 Mar

Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target

MT Newswires Live
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Kymera Therapeutics (KYMR) and Anika Therapeutics (ANIK)

TIPRANKS
·
07 Mar

Kymera Therapeutics Grants Performance Stock Units to Executives

TIPRANKS
·
04 Mar

Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges

TIPRANKS
·
01 Mar

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Zacks
·
01 Mar

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)

TIPRANKS
·
28 Feb

Kymera Therapeutics: Buy Rating Affirmed Amid Promising STAT6 Program Developments and Adjusted Price Target

TIPRANKS
·
28 Feb